77 related articles for article (PubMed ID: 9430254)
1. A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines.
Marriott JB; Cookson S; Carlin E; Youle M; Hawkins DA; Nelson M; Pearson M; Vaughan AN; Gazzard B; Dalgleish AG
AIDS Res Hum Retroviruses; 1997 Dec; 13(18):1625-31. PubMed ID: 9430254
[TBL] [Abstract][Full Text] [Related]
2. Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial.
Drenth JP; Vonk AG; Simon A; Powell R; van der Meer JW
J Pharmacol Exp Ther; 2001 Sep; 298(3):1221-6. PubMed ID: 11504824
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group.
Jacobson JM; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Wu AW; Hooton TM; Sha BE; Shikuma CM; MacPhail LA; Simpson DM; Trapnell CB; Basgoz N
J Infect Dis; 1999 Jul; 180(1):61-7. PubMed ID: 10353862
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial.
Skowron G; Stein D; Drusano G; Melbourne K; Bilello J; Mikolich D; Rana K; Agosti JM; Mongillo A; Whitmore J; Gilbert MJ
J Infect Dis; 1999 Oct; 180(4):1064-71. PubMed ID: 10479132
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Jacobson JM; Greenspan JS; Spritzler J; Ketter N; Fahey JL; Jackson JB; Fox L; Chernoff M; Wu AW; MacPhail LA; Vasquez GJ; Wohl DA
N Engl J Med; 1997 May; 336(21):1487-93. PubMed ID: 9154767
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide for the treatment of AIDS-associated wasting.
Kaplan G; Thomas S; Fierer DS; Mulligan K; Haslett PA; Fessel WJ; Smith LG; Kook KA; Stirling D; Schambelan M
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1345-55. PubMed ID: 11018854
[TBL] [Abstract][Full Text] [Related]
7. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
[TBL] [Abstract][Full Text] [Related]
8. Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16alpha-bromoepiandrosterone (HE2000).
Reading C; Dowding C; Schramm B; Garsd A; Onizuka-Handa N; Stickney D; Frincke J
Clin Microbiol Infect; 2006 Nov; 12(11):1082-8. PubMed ID: 17002607
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: a double-blind placebo-controlled clinical trial.
Ramirez-Amador VA; Esquivel-Pedraza L; Ponce-de-Leon S; Reyes-Teran G; Gonzalez-Guevara M; Ponce-de-Leon S; Sierra-Madero JG
Clin Infect Dis; 1999 Apr; 28(4):892-4. PubMed ID: 10825055
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea.
Nokta M; Rossero R; Loesch K; Pollard RB
AIDS Res Hum Retroviruses; 1997 Dec; 13(18):1633-8. PubMed ID: 9430255
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267.
Wohl DA; Aweeka FT; Schmitz J; Pomerantz R; Cherng DW; Spritzler J; Fox L; Simpson D; Bell D; Holohan MK; Thomas S; Robinson W; Kaplan G; Teppler H;
J Infect Dis; 2002 May; 185(9):1359-63. PubMed ID: 12001058
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide Celgene Corp.
Bruyn GA
IDrugs; 1998 Aug; 1(4):490-500. PubMed ID: 18465584
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients.
Haslett PA; Klausner JD; Makonkawkeyoon S; Moreira A; Metatratip P; Boyle B; Kunachiwa W; Maneekarn N; Vongchan P; Corral LG; Elbeik T; Shen Z; Kaplan G
AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1169-79. PubMed ID: 10480630
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers.
Jacobson JM; Greenspan JS; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Pulvirenti JJ; Hooton TM; Shikuma C
J Infect Dis; 2001 Jan; 183(2):343-346. PubMed ID: 11120935
[TBL] [Abstract][Full Text] [Related]
15. Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection.
Aziz N; Nishanian P; Taylor JM; Mitsuyasu RT; Jacobson JM; Dezube BJ; Lederman MM; Detels R; Fahey JL
J Infect Dis; 1999 Apr; 179(4):843-8. PubMed ID: 10068579
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis.
Tramontana JM; Utaipat U; Molloy A; Akarasewi P; Burroughs M; Makonkawkeyoon S; Johnson B; Klausner JD; Rom W; Kaplan G
Mol Med; 1995 May; 1(4):384-97. PubMed ID: 8521296
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia.
Shannon E; Noveck R; Sandoval F; Kamath B; Kearney M
Transl Res; 2007 Nov; 150(5):275-80. PubMed ID: 17964516
[TBL] [Abstract][Full Text] [Related]
18. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis.
Wolkenstein P; Latarjet J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Schuhmacher MH; Milpied B; Pilorget A; Bocquet H; Brun-Buisson C; Revuz J
Lancet; 1998 Nov; 352(9140):1586-9. PubMed ID: 9843104
[TBL] [Abstract][Full Text] [Related]
19. Effect of a four-week course of interleukin-10 on cytokine production in a placebo-controlled study of HIV-1-infected subjects.
Pott GB; Sailer CA; Porat R; Peskind RL; Fuchs AC; Angel JB; Skolnik PR; Jacobson MA; Giordano MF; Lebeaut A; Grint PC; Dinarello CA; Shapiro L
Eur Cytokine Netw; 2007 Jun; 18(2):49-58. PubMed ID: 17594937
[TBL] [Abstract][Full Text] [Related]
20. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial.
Reyes-Terán G; Sierra-Madero JG; Martínez del Cerro V; Arroyo-Figueroa H; Pasquetti A; Calva JJ; Ruiz-Palacios GM
AIDS; 1996 Nov; 10(13):1501-7. PubMed ID: 8931784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
